Part 4/Chapter 10/20-min read

Lower Extremity Arterial Disease

Peripheral artery disease from claudication to critical limb ischemia with revascularization options

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·25 sections · 56 references

Background

Lower extremity arterial occlusive disease is the most common form of peripheral arterial disease (10PAD) and represents a major cause of morbidity, disability, and health-care costs worldwide.

  • Global prevalence: >200 million people affected, with rising incidence due to aging populations and increasing rates of diabetes and smoking
  • Clinical spectrum: from asymptomatic disease → claudication → chronic limb-threatening ischemia (CLTI) → amputation.
  • Associated risk: 10PAD patients have a 2–6× higher risk of myocardial infarction, stroke, and cardiovascular death .
  • Clinical burden: ~25% of patients with CLTI undergo major amputation within 1 year, despite modern therapies.
  • Overlap with other vascular diseases: patients often have concurrent 4Aneurysms, 7carotid disease, or coronary artery disease.

Atherosclerosis (dominant cause)

  • Inflow lesions: aortoiliac.
  • Outflow lesions: femoropopliteal, tibial, pedal.
  • Risk factors: smoking, diabetes mellitus (DM), hypertension (HTN), dyslipidemia, chronic kidney disease (CKD), obesity, and sedentary lifestyle.

Other etiologies

  • Embolism: cardiac (AF, mural thrombus) or proximal arterial source. See 12VTE for thromboembolism principles.
  • Thrombosis: acute occlusion of pre-existing stenosis.
  • Vasculitis: Takayasu arteritis, Buerger disease, giant cell arteritis.
  • Trauma/Iatrogenic: vascular injury, catheterization. See 16EVTM for trauma management.
  • Radiation-induced arterial disease.

Pathophysiology

  1. Endothelial dysfunction: reduced nitric oxide, increased permeability.
  2. Plaque formation: LDL infiltration, oxidation, macrophage recruitment → foam cells.
  3. Progression: fibrous cap, calcification, narrowing lumen.
  4. Complications: thrombosis, embolization, plaque rupture.
  5. Microcirculation: impaired autoregulation, collateral failure, tissue hypoxia.

Patterns of Disease

  • Aortoiliac: Leriche syndrome (claudication, impotence, absent femoral pulses).
  • Femoropopliteal: most common site.
  • Infrapopliteal/tibial: common in diabetes mellitus (DM) and renal failure, often presenting as chronic limb-threatening ischemia (CLTI). Patients with DM typically exhibit more distal, multi-level disease patterns and increased medial arterial calcification (MAC).

Asymptomatic disease

  • Detected by an abnormal ankle-brachial index (ABI) (<0.9). Assessment of subclinical atherosclerosis in asymptomatic populations is increasingly recognized as a critical tool for cardiovascular risk stratification .
  • Associated with high systemic cardiovascular (CV) risk and a substantial global health burden .

Claudication

  • Exercise-induced, reproducible muscle pain relieved by rest.
  • Localizes to site: buttock (aortoiliac), thigh (femoral), calf (femoropopliteal), foot (tibial).

Chronic Limb-Threatening Ischemia

Risk stratification: The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) (Wound, Ischemia, foot Infection) classification provides standardized staging of threatened limbs (Stages 1–4) to predict 1-year amputation risk and estimate the benefit of revascularization. Ischemia grading incorporates objective measures—toe pressure and transcutaneous oxygen tension (TcPO₂)—per WIfI criteria. WIfI is complemented by the Global Limb Anatomic Staging System (GLASS), which characterizes anatomic complexity (Stages I–III) along the Target Arterial Path (TAP). The Global Vascular Guidelines advocate integrating these dimensions into the PLAN framework—Patient risk, Limb severity (WIfI), and ANatomic pattern (GLASS)—to guide individualized revascularization strategy .

WIfI Classification Summary

ClassificationAnkle-brachial index (ABI) ≥0.8, TP ≥60
0
**Wound (W)**
No wound
**Ischemia (I)**
ankle-brachial index (ABI) ≥0.8, TP ≥60
**foot Infection (fI)**
No infection
1
**Wound (W)**
Small/shallow
**Ischemia (I)**
ABI 0.6–0.79, TP 40–59
**foot Infection (fI)**
Mild/local
2
**Wound (W)**
Deeper/larger
**Ischemia (I)**
ABI 0.4–0.59, TP 30–39
**foot Infection (fI)**
Moderate
3
**Wound (W)**
Extensive/gangrene
**Ischemia (I)**
ABI <0.4, TP <30
**foot Infection (fI)**
Severe/systemic

Acute Limb Ischemia

  • Classic presentation—the 6 Ps: Pain, Pallor, Pulselessness, Paresthesia, Paralysis, and Poikilothermia (coolness) . Motor and sensory deficits indicate advanced ischemia requiring urgent intervention.
  • Immediate management: Systemic anticoagulation with intravenous unfractionated heparin (UFH) (unless contraindicated) should be initiated immediately to prevent thrombus propagation. Severity staging using the Rutherford classification (I–III) guides treatment urgency. Catheter-directed thrombolysis (CDT) or endovascular thrombectomy (ET) are appropriate for Rutherford I–IIa (viable or marginally threatened limb without motor deficit). Recent meta-analyses indicate that ET provides comparable limb salvage rates to CDT while potentially reducing procedural time and bleeding risks . Rutherford IIb (immediately threatened limb with motor deficit) requires emergent surgical or endovascular revascularization within hours to prevent irreversible tissue loss. Rutherford III (irreversible ischemia with rigor and fixed mottling) contraindicates revascularization due to futility and high risk of reperfusion injury, compartment syndrome, and systemic complications . In pediatric populations, management of acute limb ischemia (ALI) requires specialized consideration of vessel size and etiology, with a focus on anticoagulation and tailored surgical or endovascular approaches .

Rutherford ALI Classification

ClassificationClass and Description and Sensory Loss
  • I
    **Management**
    Elective revascularization
    **Description**
    Viable
    **Sensory Loss**
    None
    **Motor Deficit**
    None
  • IIa
    **Management**
    Urgent revascularization
    **Description**
    Marginally threatened
    **Sensory Loss**
    Minimal (toes)
    **Motor Deficit**
    None
  • IIb
    **Management**
    Emergent revascularization
    **Description**
    Immediately threatened
    **Sensory Loss**
    Beyond toes
    **Motor Deficit**
    Mild-moderate
  • III
    **Management**
    Primary amputation
    **Description**
    Irreversible
    **Sensory Loss**
    Profound, anesthetic
    **Motor Deficit**
    Paralysis (rigor)

Clinical evaluation

Ankle-Brachial Index (ABI): <0.9 indicates peripheral arterial disease (PAD); <0.5 indicates severe ischemia; >1.3 suggests arterial calcification (medial sclerosis), commonly seen in diabetes and chronic kidney disease.

Imaging Studies

Imaging Modalities for peripheral arterial disease (PAD)

DiagnosticDuplex Ultrasound (DUS)
Duplex Ultrasound (DUS)
**Indications**
First-line screening
**Advantages**
No radiation/contrast, peak systolic velocity (PSV) ratios
**Limitations**
Operator-dependent, limited by calcification
computed tomography angiography (CTA)
**Indications**
Surgical planning
**Advantages**
Detailed anatomy, fast
**Limitations**
Contrast, radiation, calcium blooming artifacts
magnetic resonance angiography (MRA)
**Indications**
Contrast allergy, chronic kidney disease (CKD)
**Advantages**
No radiation
**Limitations**
Longer scan time, overestimates stenosis
digital subtraction angiography (DSA)
**Indications**
Intra-procedural
**Advantages**
Gold standard, therapeutic
**Limitations**
Invasive, contrast
  • Duplex Ultrasound (DUS): first-line imaging modality; uses PSV ratios to grade stenosis severity (PSV ratio >2.0 indicates ≥50% stenosis). In patients with diabetes, medial arterial calcification can significantly limit the accuracy of DUS due to acoustic shadowing .
  • Computed Tomography Angiography (CTA): provides detailed anatomic mapping of the entire arterial tree; preferred for planning revascularization in most patients. To ensure value-based care, CTA should be reserved for patients where revascularization is clinically indicated to avoid imaging misallocation .
  • Magnetic Resonance Angiography (MRA): alternative cross-sectional imaging when CTA is contraindicated (renal insufficiency, contrast allergy); gadolinium-based agents carry lower nephrotoxicity risk.
  • Digital Subtraction Angiography (DSA): intra-procedural gold standard for anatomic assessment; allows simultaneous diagnosis and therapeutic intervention. DSA is generally not recommended for primary diagnosis alone when non-invasive options are available . See 3Chapter 3 for comprehensive imaging principles.

Functional tests

  • Exercise Treadmill Test: quantifies functional impairment by measuring pain-free walking distance and maximum walking distance. Standardized protocols (e.g., 2 mph at 10% grade) enable reproducible assessment of treatment response.
  • Transcutaneous Oxygen Tension (TcPO₂): measures skin surface oxygen tension to assess microcirculatory perfusion. Values <30 mmHg predict poor wound healing without revascularization; values >40 mmHg indicate adequate perfusion for wound healing.

Medical Therapy

  • Risk factor modification: smoking cessation (most critical intervention), blood pressure control (target <130/80 mmHg), optimal diabetes management (hemoglobin A1c [HbA1c] <7%) , and lipid management.
  • Supervised exercise therapy (SET): structured walking programs (3 sessions/week, 30–60 minutes) improve claudication distance by 50–200% and remain a Class I recommendation . Recent systematic reviews confirm SET as a primary non-invasive treatment for improving both maximal and pain-free walking distances .
  • Antiplatelet therapy: aspirin (75–325 mg daily) or clopidogrel (75 mg daily). The CAPRIE trial demonstrated clopidogrel superiority in the peripheral arterial disease (PAD) subgroup (8.7% relative risk reduction; p=0.0028) .
  • Statin therapy: high-intensity therapy (e.g., atorvastatin 40–80 mg) reduces cardiovascular events and limb events (HPS, SPARCL trials). Target low-density lipoprotein (LDL) <70 mg/dL, or <55 mg/dL in very high-risk patients .
  • Dual-pathway inhibition: rivaroxaban 2.5 mg BID plus aspirin reduces major adverse cardiovascular events (MACE) and major adverse limb events (MALE) by 24% (COMPASS trial), with increased but manageable bleeding risk .
  • Cilostazol: phosphodiesterase-3 inhibitor that increases walking distance and improves quality of life; 100 mg twice daily (not approved in Europe due to concerns about cardiac safety). The 2025 Society for Vascular Surgery (SVS) focused update reaffirms its efficacy for patients with intermittent claudication (IC) .
  • Post-revascularization antithrombotic therapy: after lower extremity revascularization (LER), rivaroxaban 2.5 mg BID plus aspirin reduces acute limb ischemia (ALI) and MACE compared with aspirin alone (VOYAGER-PAD), balancing efficacy against increased bleeding risk in appropriate candidates . Recent evidence highlights significant practice variations in antithrombotic selection and the potential role of extended clopidogrel therapy .

Endovascular therapy

  • Aortoiliac interventions: angioplasty with selective stenting has been a historical standard, but primary stenting is now preferred for common and external iliac artery lesions due to superior patency (5-year patency >85%). Kissing-balloon technique is used for aortic bifurcation lesions.
  • Femoropopliteal interventions:
    • Plain old balloon angioplasty (POBA): initial treatment for short, focal lesions; limited by high restenosis rates (30–60% at 1 year).
    • Drug-coated balloons (DCB): paclitaxel-eluting balloons reduce restenosis compared with POBA (IN.PACT SFA and LEVANT 2 trials: ~65–70% vs ~50% primary patency at 1 year). Recent guidelines for intermittent claudication (IC) favor DCB or drug-eluting stents (DES) over POBA for improved long-term patency.
    • Nitinol bare-metal stents (BMS): self-expanding stents for long lesions or POBA failure; subject to in-stent restenosis and stent fracture.
    • Drug-eluting stents (DES): polymer-based paclitaxel stents (e.g., Zilver PTX) improve patency over BMS in intermediate-length SFA lesions.
    • Covered stents: ePTFE-lined stents (e.g., Viabahn) for long occlusions or aneurysmal segments; higher profile limits use in small vessels.
    • Atherectomy and intravascular lithoplasty: adjunctive therapies for heavily calcified lesions to facilitate balloon angioplasty and reduce dissection. However, routine use of atherectomy for IC is not recommended due to a lack of high-quality evidence demonstrating superior clinical outcomes over angioplasty alone.
  • Infrapopliteal interventions: balloon angioplasty remains the primary approach for tibial arteries in chronic limb-threatening ischemia (CLTI); drug-eluting stents or DCB may be considered for focal lesions. Retrograde (pedal) access is used when antegrade crossing fails. For patients with IC, infrapopliteal endovascular intervention is generally not recommended.
  • Outcomes: endovascular therapy achieves high initial technical success (>90%), but restenosis remains a significant limitation, particularly in long femoropopliteal and tibial lesions, necessitating surveillance and reintervention.

Open surgery

Selection of bypass versus endovascular therapy in chronic limb-threatening ischemia (CLTI) is guided by conduit availability, anatomic complexity, and patient factors, including comorbidities and socioeconomic status (SES). In patients with diabetes mellitus (DM), the 2026 ACC/AHA guidelines emphasize that revascularization decisions should occur within a multidisciplinary framework to optimize limb salvage and manage the high systemic cardiovascular risk associated with the disease . Furthermore, SES has been identified as a critical determinant of access to care and long-term outcomes following revascularization for peripheral artery disease (PAD) .

The Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb-Threatening Ischemia (BEST-CLI) trial demonstrated that when single-segment great saphenous vein (GSV) is available and anatomic complexity is high (Global Anatomic Staging System [GLASS] Stage III or extensive tibial disease), a bypass-first strategy produces superior limb salvage and amputation-free survival (AFS) compared with best endovascular therapy (cohort 1). Conversely, when adequate autogenous conduit is unavailable or anatomic complexity is lower (GLASS I–II), endovascular-first and bypass-first approaches achieve comparable outcomes (cohort 2). The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial supports bypass-first strategy in patients with life expectancy exceeding 2 years, whereas angioplasty-first is appropriate for patients with limited longevity or prohibitive surgical risk .

For popliteal artery aneurysm causing acute limb ischemia (ALI), see 5Chapter 5.

Hybrid procedures

Hybrid procedures combine open surgical and endovascular techniques in a single session or staged approach to treat multilevel disease efficiently. Representative hybrid strategy: common femoral artery (CFA) endarterectomy with patch angioplasty to restore inflow, followed by ipsilateral retrograde iliac artery stenting and/or antegrade superficial femoral artery (SFA) intervention. This approach leverages the durability of CFA endarterectomy while minimizing the morbidity of extensive open reconstruction. Hybrid procedures are increasingly utilized for complex multilevel occlusive disease, particularly in patients with aortoiliac inflow lesions combined with infrainguinal outflow disease, achieving outcomes comparable to staged or purely open approaches with shorter hospital stays .

Follow-up

Post-Revascularization Surveillance Protocol

SurveillanceDuplex ultrasound (DUS)
  • **1 mo**
    ✓
    **6 mo**
    ✓
    **12 mo**
    ✓
    **Annual**
    ✓
  • ankle-brachial index (ABI)/toe-brachial index (TBI)
    **1 mo**
    ✓
    **6 mo**
    ✓
    **12 mo**
    ✓
    **Annual**
    ✓
  • Clinical exam
    **1 mo**
    ✓
  • Surveillance:
    • Duplex ultrasound (DUS) at 1, 6, and 12 months post-intervention, then annually, to detect hemodynamically significant restenosis (peak systolic velocity [PSV] ratio >2.5 or >50% diameter reduction).
    • Ankle-brachial index (ABI) or toe-brachial index (TBI) and clinical examination at each visit to assess functional status and symptom recurrence.
  • Restenosis:
    • More frequent after endovascular intervention (30–60% at 1–2 years) than open bypass. Hemodynamically significant restenosis (>70% stenosis or symptoms) warrants reintervention with repeat angioplasty, stenting, or conversion to bypass.
  • Medical therapy: Lifelong antiplatelet therapy (aspirin or clopidogrel) and high-intensity statin therapy are mandatory to reduce systemic cardiovascular events and improve graft patency. Consider dual-pathway inhibition (rivaroxaban 2.5 mg BID + aspirin) in appropriate candidates post-revascularization. In patients with diabetes mellitus, optimized glycemic control and comprehensive management of metabolic risk factors are essential to mitigate the high risk of major adverse limb events (MALE) and cardiovascular complications .
  • Wound care: Multidisciplinary wound management—including pressure offloading, debridement, infection control, and glycemic optimization—is essential in chronic limb-threatening ischemia (CLTI) patients to maximize limb salvage after revascularization. This integrated approach is particularly critical for patients with diabetes to ensure timely healing and prevent recurrence .
  • Registry participation and Outcomes: National registries (e.g., Swedvasc, Vascunet) track long-term outcomes and provide quality benchmarks for institutional performance evaluation and continuous quality improvement. Surveillance and registry data should also account for socioeconomic status (SES), as lower SES is associated with poorer long-term outcomes and higher rates of major amputation following vascular interventions .

Tables

Table 7.1ClassificationFontaine and Rutherford Classification of peripheral artery disease (PAD)
I
**Rutherford Category**
0
**Clinical Presentation**
Asymptomatic
IIa/IIb
**Rutherford Category**
1–3
**Clinical Presentation**
Claudication (mild–severe)
III
**Rutherford Category**
4
**Clinical Presentation**
Rest pain
IV
**Rutherford Category**
5–6
**Clinical Presentation**
Ulcer/gangrene
Table 7.2GuidelinesEvidence-Based Medical Therapy in PAD
Antiplatelet (aspirin vs clopidogrel)
**Trial**
CAPRIE
**Key Finding**
Clopidogrel > aspirin in PAD subgroup
Statins
**Trial**
HPS, SPARCL
**Key Finding**
↓ cardiovascular (CV) and limb events
Rivaroxaban (2.5 mg BID) + aspirin
**Trial**
COMPASS, VOYAGER PAD
**Key Finding**
↓ major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in stable disease and post-revascularization
SGLT2 inhibitors / GLP-1 RA
**Trial**
Meta-analysis
**Key Finding**
↓ MACE and MALE in patients with PAD and diabetes
Exercise therapy
**Trial**
Cochrane meta-analysis
**Key Finding**
↑ Walking distance 50–200%
Cilostazol
**Trial**
Meta-analysis
**Key Finding**
↑ Claudication distance, symptom relief
Table 7.3Endovascular vs Open Surgery for PAD
Comparison A

Angioplasty (plain old balloon angioplasty (POBA))

Trade-offs
  • Not durable
Comparison B

Drug-coated balloon (DCB)

Trade-offs
  • Cost
Comparison C

Drug-eluting stent (DES)

Trade-offs
  • Limited length
Comparison D

Covered stents

Trade-offs
  • Risk of stent fracture
Comparison E

Bypass (vein)

Trade-offs
  • Surgical risk
Comparison F

Prosthetic bypass

Trade-offs
  • Inferior durability

References

  1. Fowkes FGR, et al. Global prevalence of PAD. Lancet. 2013. PubMed
  2. Hiatt WR, et al. PAD as systemic disease. NEJM. 2015. PubMed
  3. CAPRIE Steering Committee. Clopidogrel vs aspirin in ischemic disease. Lancet. 1996. PubMed
  4. Eikelboom JW, et al. COMPASS trial. NEJM. 2017. PubMed
  5. Conte MS, et al. Global Vascular Guidelines on CLTI. J Vasc Surg. 2019. PubMed
  6. Aboyans V, et al. ESVS/SVS Guidelines on PAD. Eur J Vasc Endovasc Surg. 2018. PubMed
  7. Gornik HL, et al. 2024 ACC/AHA/SVS Guideline for the Management of Lower Extremity Peripheral Artery Disease. J Am Coll Cardiol. 2024. PMID: 38752899.
  8. Uyagu OD, et al. Quality assessment and comparative analysis on the recommendations of current guidelines on screening and diagnosis of peripheral arterial disease. BMJ Open. 2022. PMID: 36104133.

SVS WIfI wound classification system for CLTI risk stratification

The Society for Vascular Surgery (SVS) Wound, Ischemia, and foot Infection (WIfI) classification system stratifies chronic limb-threatening ischemia (CLTI) risk by combining three domains: Wound (W0–3), Ischemia (I0–3), and foot Infection (fI0–3) to generate an overall limb threat stage (Stages 1–4). Higher WIfI stages correlate with increased 1-year amputation risk and greater potential benefit from revascularization. The ACC/AHA guidelines on management of lower extremity peripheral artery disease (PAD) reinforce WIfI as the preferred classification system for risk stratification and clinical decision-making in adults with diabetes and CLTI . Objective ischemia thresholds include toe pressure (I0: ≥40 mmHg; I1: 30–39 mmHg; I2: <30 mmHg; I3: <30 mmHg with rest pain) and transcutaneous oxygen tension (TcPO₂; I0: ≥40 mmHg; I1: 30–39 mmHg; I2: <30 mmHg; I3: <30 mmHg with rest pain). WIfI should be documented at baseline and reassessed after revascularization to evaluate treatment response .

Educational summary

WIFI

Interactive, patient-specific calculator inputs are disabled on public chapter pages.

This widget is shown as a reference-only note and does not provide clinical recommendations.

Classification1 (Very low)
1 (Very low)
**1-Year Amputation Risk**
<5%
**Revascularization Benefit**
Low
2 (Low)
**1-Year Amputation Risk**
5–10%
**Revascularization Benefit**
Moderate
3 (Moderate)
**1-Year Amputation Risk**
10–20%
**Revascularization Benefit**
High
4 (High)
**1-Year Amputation Risk**
>20%
**Revascularization Benefit**
Very high

GLASS (Global Limb Anatomic Staging System) and Target Arterial Path (TAP)

The Global Limb Anatomic Staging System (GLASS) categorizes anatomic complexity using stages I–III based on lesion severity in the femoropopliteal and infrapopliteal segments along a selected Target Arterial Path (TAP)—the single most appropriate arterial route to the foot. GLASS stage, integrated with Wound, Ischemia, and foot Infection (WIfI) and patient risk factors, forms the PLAN framework (Patient risk, Limb severity [WIfI], ANatomic complexity [GLASS]) recommended in the Global Vascular Guidelines. This integrated assessment guides treatment strategy: lower GLASS stages (I–II) favor an endovascular-first approach, while higher complexity (GLASS III) with available autogenous conduit supports bypass-first revascularization .

GLASS Anatomic Staging

ClassificationGLASS Stage and Femoropopliteal and Infrapopliteal
I
**Femoropopliteal**
Focal, <10 cm
**Infrapopliteal**
Focal, single vessel
**Treatment Preference**
Endovascular-first
II
**Femoropopliteal**
Intermediate, 10–20 cm
**Infrapopliteal**
Multiple focal
**Treatment Preference**
Either approach
III
**Femoropopliteal**
Extensive, >20 cm or CTO
**Infrapopliteal**
Extensive, poor runoff
**Treatment Preference**
Bypass-first (if vein available)

Bypass vs endovascular selection for CLTI (BASIL and BEST-CLI)

The BEST-critical limb ischemia (CLI) trial provides level-1 evidence for revascularization strategy in chronic limb-threatening ischemia (CLTI). In cohort 1 (patients with adequate single-segment great saphenous vein and complex anatomy—GLASS III or extensive tibial disease), bypass-first surgery achieved superior outcomes including reduced major amputation and improved amputation-free survival compared with best endovascular therapy. In cohort 2 (patients without adequate autogenous conduit or with less complex anatomy—GLASS I–II), bypass using prosthetic conduit and endovascular-first approaches demonstrated similar outcomes, supporting an endovascular-first strategy in this subset. The BASIL trial provides complementary long-term data: bypass-first strategy confers survival and amputation-free survival benefits in patients with anticipated longevity exceeding 2 years, whereas angioplasty-first is appropriate for patients with limited life expectancy or prohibitive surgical risk, given equivalent 6-month outcomes and reduced perioperative morbidity .

Acute limb ischemia: initial management and timing of revascularization

Initial management of acute limb ischemia requires immediate systemic anticoagulation with intravenous unfractionated heparin (unless contraindicated) to prevent thrombus propagation, followed by rapid severity classification using the Rutherford system (I–III). Treatment selection is time-sensitive and severity-dependent: catheter-directed thrombolysis is appropriate for Rutherford I–IIa (viable or marginally threatened limb without motor deficit); Rutherford IIb (immediately threatened limb with motor deficit) requires emergent revascularization within hours, often via surgical thrombectomy; Rutherford III (irreversible ischemia with rigor) contraindicates revascularization due to high risk of reperfusion injury, systemic complications, and futility .

Post-revascularization antithrombotic therapy (VOYAGER-PAD)

The VOYAGER-peripheral arterial disease (PAD) trial demonstrated that dual-pathway inhibition with rivaroxaban 2.5 mg twice daily plus aspirin after lower extremity revascularization significantly reduces acute limb ischemia and major adverse cardiovascular events (MACE) compared with aspirin alone, though at the cost of increased major bleeding (TIMI major bleeding 2.65% vs 1.87%; p=0.07). This regimen is recommended for appropriate patients without contraindications or high bleeding risk, balancing the absolute risk reduction in limb and cardiovascular events (~1.5% per year) against bleeding complications .

Post-Revascularization Antithrombotic Options

GuidelinesAspirin Alone
  • **Trial**
    Standard
    **Benefit**
    Baseline
    **Bleeding Risk**
    Low
    **Candidate**
    High bleeding risk
  • Aspirin + Rivaroxaban 2.5 mg BID
    **Trial**
    VOYAGER-PAD
    **Benefit**
    ↓ ALI, MACE
    **Bleeding Risk**
    Moderate
    **Candidate**
    Standard risk
  • DAPT (Aspirin + Clopidogrel)
    **Trial**
    CAPRIE
    **Benefit**
    ↓ CV events
    **Bleeding Risk**
    Moderate
    **Candidate**
    Post-stent

Chronic limb-threatening ischemia (CLTI) modern paradigm

Chronic limb-threatening ischemia (CLTI) represents the most severe manifestation of 10peripheral artery disease, characterized by rest pain, tissue loss, or gangrene lasting more than 2 weeks. Contemporary classification systems provide a structured framework for decision-making:

  • Wound, Ischemia, and foot Infection (WIfI) staging (Wound, Ischemia, foot Infection) stratifies limb-threat severity and guides revascularization decisions.
  • GLASS classification (Global Limb Anatomic Staging System) categorizes anatomic complexity of arterial disease.
  • PLAN concept (Patient risk, Limb threat, ANatomic pattern) integrates patient-specific factors to individualize revascularization strategy.

Hemodynamic assessment is critical in CLTI. A toe pressure less than 30 mmHg or transcutaneous oxygen tension (TcPO₂) less than 25–30 mmHg indicates severe ischemia with poor wound-healing potential. In diabetic patients with medial arterial calcification, toe pressures provide more reliable assessment than ankle pressures, as calcified arteries may be noncompressible and yield falsely elevated ankle-brachial indices .

For venous causes of leg ulcers, see 13CVI.

Drug-coated device (paclitaxel) safety

The safety of paclitaxel-coated devices in femoropopliteal peripheral artery disease has been the subject of considerable controversy. A 2018 meta-analysis suggested increased late mortality with paclitaxel-coated balloons and stents compared to uncoated devices , prompting regulatory warnings and clinical concern.

However, subsequent large real-world analyses, including the Medicare-based SAFE-peripheral arterial disease (PAD) study, did not confirm an increased mortality signal through mid-term follow-up . Multiple additional analyses have yielded conflicting results, and the biological mechanism for any potential mortality signal remains unclear.

Regulatory agencies have issued advisories recommending informed discussion with patients about the uncertain risks and benefits. Current practice emphasizes shared decision-making, consideration of alternative technologies (plain balloon angioplasty, bare-metal stents, atherectomy), and individualized risk-benefit assessment. Clinicians should remain aware of evolving evidence and regulatory guidance in this area.

References

  1. 1.
    Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease. Circulation. 2017;135(12):e726-e779.
    PubMed-indexed article2016

    The Task Force recognizes the need for objective, independent Evidence Review Committees that include methodologists, epidemiologists, clinicians, and biostatisticians who systematically survey, abstract, and assess the evidence to address systematic review questions posed in the PICOTS format.

    PubMedOpen PDF
  2. 2.
    Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S-125S.e40.
    PubMed-indexed article2019

    The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP) resulting in three stages of complexity for intervention.

    PubMedOpen PDF
  3. 3.
    Fowkes FGR, et al. Global prevalence of PAD. *Lancet*. 2013. PubMed. Prevalence study.
    PubMed-indexed article2013

    This study provides the first comparison of the prevalence of peripheral artery disease between high-income countries (HIC) and low-income or middle- income countries (LMIC), establishes the primary risk factors for peripheral artery diseases in these settings, and estimates the number of people living with peripheral artery Disease regionally and globally.

    PubMedDOI
  4. 4.
    GBD 2019 Vascular Disease Collaborators. Global burden of vascular disease. *Lancet*. 2020. PubMed. Global epidemiology.
    PubMed-indexed article2020

    Georgia has a high NCD burden and results from the survey showed an increase in obesity and elevated blood pressure since 2010, and comprehensive public health interventions are needed to control the heath security threats of major NCDs and their risk factors in the future.

    PubMedDOIOpen PDF
  5. 5.
    Hiatt WR, et al. PAD as systemic disease. *NEJM*. 2015. PubMed
    PubMed-indexed article2015

    In vitro experiments demonstrated that exposure to Omniscan resulted in the release of catalytic iron and this was prevented by the iron chelator deferiprone, and an important role of iron in the pathophysiology of gadolinium chelate toxicity and nephrogenic systemic fibrosis is supported.

    PubMedDOIOpen PDF
  6. 6.
    Martin SS et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024. PMID: 38264914.
    PubMed-indexed article2024
    PubMedDOI
  7. 7.
    Norgren L, et al. Inter-Society Consensus for PAD (TASC II). *J Vasc Surg*. 2007;45:S5–67. PubMed. PAD classification guideline.
    PubMed-indexed article2007
    PubMed
  8. 8.
    Tsao CW et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023. PMID: 36695182.
    PubMed-indexed article2023
    PubMedDOI
  9. 9.
    Feliciano DV, et al. EAST Guidelines for extremity vascular trauma. *J Trauma*. 2011. PubMed
    PubMed-indexed article2011

    There have been changes in practice since the publication of the previous guidelines for the evaluation and treatment of penetrating lower extremity arterial trauma, and the role of endovascular intervention warrants further investigation.

    PubMedOpen PDF
  10. 10.
    Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000;343:864–869.
    PubMed-indexed article2000

    The pathological description in 1908 of Buerger’s disease was so accurate and detailed that little has been added over the last century.

    PubMedDOI
  11. 11.
    Rutherford RB (ed.). *Rutherford’s Vascular Surgery and Endovascular Therapy.* 9th Ed. Philadelphia: Elsevier; 2018. Authoritative textbook.
    Textbook referenceTextbook2018
    Source
  12. 12.
    Libby P. The changing landscape of atherosclerosis. *Nature*. 2021;592:524–33. PubMed. Mechanistic insights.
    PubMed-indexed article2021

    Advances in understanding of the biology of atherosclerosis have opened avenues to therapeutic interventions that promise to improve the prevention and treatment of now-ubiquitous atherosclerotic diseases.

    PubMedDOI
  13. 13.
    ACC/AHA. Management of Lower Extremity Peripheral Artery Disease: Guidelines From the ACC/AHA. 2026. PMID: 41252847.
    PubMed-indexed articleClinical practice guideline2026
    PubMed
  14. 14.
    Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed. 2022. Ch. 19, Clinical Evaluation of the Arterial System, p. 309
    Textbook
    Textbook referenceTextbook2022

    Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed.. 2022. Ch. 19, Clinical Evaluation of the Arterial System, p. 309

    Textbook reference
  15. 15.
    Aboyans V, et al. Measurement and interpretation of ABI. *Circulation*. 2012;126:2890–909. PubMed. ABI standardization.
    PubMed-indexed article2012
    PubMedDOIOpen PDF
  16. 16.
    Garg PK et al. Assessment of Subclinical Atherosclerosis in Asymptomatic People In Vivo: Measurements Suitable for Biomarker and Mendelian Randomization Studies. Arterioscler Thromb Vasc Biol. 2023. PMID: 38150519.
    PubMed-indexed articleMeta-analysis / systematic review2023
    PubMedDOI
  17. 17.
    Martin SS et al. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025. PMID: 39866113.
    PubMed-indexed article2025

    The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.

    PubMedDOI
  18. 18.
    Conte MS, et al. Global Vascular Guidelines on CLTI. *J Vasc Surg*. 2019. PubMed
    PubMed-indexed article2019

    The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention.

    PubMedDOIOpen PDF
  19. 19.
    Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on WIfI (wound, ischemia, and foot infection). J Vasc Surg. 2014;59(1):220–234.e2.
    PubMed-indexed article2014

    Water-soluble gold nanoparticles functionalized by sodium 3-mercapto-1-propansulfonate (Au-3MPS) were synthesized with different Au/thiol molar ratios for their ability to interact with biomolecules and display high potential in biotechnological and biomedical applications, mainly for the loading and release of water insoluble drugs.

    PubMed
  20. 20.
    Kusumowardani AR et al. Endovascular Thrombectomy or Catheter-Directed Thrombolysis for Acute Limb Ischemia: Insights From a Systematic Review and Meta-Analysis. Journal of Endovascular Therapy. 2026. PMID: 41877595.
    PubMed-indexed articleMeta-analysis / systematic review2026
    PubMedDOI
  21. 21.
    Meyer J et al. A systematic review of the management of acute limb ischemia in children. Journal of Vascular Surgery. 2026. PMID: 41866093.
    PubMed-indexed articleMeta-analysis / systematic review2026
    PubMedDOI
  22. 22.
    Moneta GL, et al. Duplex ultrasound criteria for PAD. *J Vasc Surg*. 2010;52: 539–48. PubMed. DUS accuracy.
    PubMed-indexed article2010

    In patients with severe upper extremity ischemia not amenable to standard revascularization techniques, AVR should be considered to provide limb salvage and maximize hand function.

    PubMedOpen PDF
  23. 23.
    Prince MR, et al. MR angiography: principles and clinical applications. *Radiology*. 2016;281:630–48. PubMed. MRA overview.
    PubMed-indexed article2016

    99mTc-labeled PSMA inhibitor MIP-1404 is a promising SPECT tracer for detection of locally recurrent or metastatic prostate cancer.

    PubMed
  24. 24.
    Raskin D et al. A narrative review of imaging misallocation in peripheral artery disease: a value-based medicine perspective. Cardiovasc Diagn Ther. 2025. PMID: 41509627.
    PubMed-indexed articleClinical practice guideline2025
    PubMedDOI
  25. 25.
    White CJ. Catheter-based angiography. *Circulation*. 2006;113:1460–8. PubMed. Diagnostic gold standard.
    PubMed-indexed article2006

    Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) A Collaborative Report from the American Association for Vascular Surgery/Society for V vascular surgery,* Society for Cardiovascular Angiography and Interventions, Society forVascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines.

    PubMedOpen PDF
  26. 26.
    Schepers A, et al. Predictive value of TcPO₂ in CLTI. *Eur J Vasc Endovasc Surg*. 2010;40:647–52. PubMed. TcPO₂ evidence.
    PubMed-indexed article2010

    In the long term, inframalleolar bypass is a satisfactory option for limb salvage and female sex was associated with worse results for cumulative patency and limb salvage.

    PubMedDOIOpen PDF
  27. 27.
    Amarenco P, et al. SPARCL trial (statins in stroke). *NEJM*. 2006. PubMed
    PubMed-indexed article2006

    In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke.

    PubMedDOIOpen PDF
  28. 28.
    Armstrong EJ, Wu J, Singh GD, Dawson DL, Pevec WC, Amsterdam EA, Laird JR. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60(6):1565-1571.
    PubMed-indexed articleRegistry / cohort2014

    The hypothesis that a silver-eluting alginate topical surgical dressing would lower wound complication rates in patients undergoing open arterial procedures in the lower extremity was tested by way of an investigator initiated clinical trial.

    PubMedDOI
  29. 29.
    Conte MS et al. Society for Vascular Surgery Clinical Practice Guideline on the management of intermittent claudication: Focused update. Journal of Vascular Surgery. 2025. PMID: 40316185.
    PubMed-indexed articleMeta-analysis / systematic review2025
    PubMedDOI
  30. 30.
    Eikelboom JW, et al. Rivaroxaban with aspirin in stable vascular disease (COMPASS). *NEJM*. 2017;377:1319–30. PubMed. Anticoagulation.
    PubMed-indexed article2017

    Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.

    PubMedDOIOpen PDF
  31. 31.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals. Lancet. 2002;360(9326):7-22.
    PubMed-indexed article2002

    Adding simvastatin to existing treatments safely produces substantial additional benefits for a wide range of high-risk patients, irrespective of their initial cholesterol concentrations.

    PubMed
  32. 32.
    CAPRIE Steering Committee. Clopidogrel vs aspirin in atherothrombosis. *Lancet*. 1996;348:1329–39. PubMed. Antiplatelet RCT.
    PubMed-indexed article1996

    TAK-029 may be effective in patients suffering from arterial thrombosis diseases, which are refractory to these conventional antithrombotic agents, and in humans, guinea pigs and monkeys.

    PubMed
  33. 33.
    Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017;12(12):CD000990.
    Cochrane LibraryMeta-analysis / systematic review2017

    The goal was to determine whether an exercise programme was effective in alleviating symptoms and increasing walking treadmill distances and walking times in people with intermittent claudication, and to assess the overall quality of evidence supporting the outcomes assessed in this review.

    PubMedDOIOpen PDFSource
  34. 34.
    Saadi S et al. A systematic review supporting the Society for Vascular Surgery guideline update on the management of intermittent claudication. Journal of Vascular Surgery. 2025. PMID: 40316186.
    PubMed-indexed articleMeta-analysis / systematic review2025
    PubMedDOI
  35. 35.
    Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314-1319.
    PubMed-indexed articleMeta-analysis / systematic review2002

    It is concluded that cilostazol significantly increases walking distance and quality-of-life measures in patients with claudication without major adverse effects.

    PubMedDOISource
  36. 36.
    Bonaca MP, Bauersachs RM, Anand SS, Debus ES, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382:1994-2004.
    PubMed-indexed article2020

    In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.

    PubMedOpen PDF
  37. 37.
    Wells N et al. Variations in antithrombotic prescriptions and evaluation of extended clopidogrel therapy after lower extremity revascularization for peripheral artery disease. Journal of Vascular Surgery. 2025. PMID: 40122313.
    PubMed-indexed articleClinical practice guideline2025
    PubMedDOI
  38. 38.
    Willigendael EM, et al. Smoking and PAD. *J Vasc Surg*. 2004. PubMed
    PubMed-indexed article2004

    Smoking is a potent risk factor for symptomatic PAD, with an important and consistent dose-response relationship, with the persistence of high risk for PAD in former smokers, tobacco control programs should continue to advocate smoking cessation, but focus even more on preventing future generations from ever starting to smoke.

    PubMedDOIOpen PDF
  39. 39.
    Dake MD, et al. Zilver PTX trial: drug-eluting stent. *NEJM*. 2011;364:1873–83. PubMed. DES for PAD.
    PubMed-indexed article2011

    Femoropopliteal peripheral artery disease treatment with the paclitaxel-eluting stent was associated with superior 12-month outcomes compared with PTA and provisional bare metal stent placement.

    PubMedDOIOpen PDF
  40. 40.
    Rosenfield K, et al. LEVANT 2: drug-coated balloon. *Circulation*. 2015;132:2131–40. PubMed. DCB outcomes.
    PubMed-indexed article2015

    LEVANT 2 represents the first US-inclusive multicenter, randomized controlled trial to assess the safety and efficacy of a novel DCB compared with PTA as primary therapy for symptomatic PAD on the background of standard medical therapy.

    PubMedDOIOpen PDF
  41. 41.
    Tepe G, et al. IN.PACT SFA trial: drug-coated balloon. *Circulation*. 2015;131:495–502. PubMed. Endovascular therapy.
    PubMed-indexed article2015

    DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease and in this prospective, multicenter, randomized trial, the primary efficacy end point was primary patency.

    PubMedDOIOpen PDF
  42. 42.
    Zil-E-Ali A et al. A systematic review to examine the impact of socioeconomic status on revascularization for peripheral arterial disease, carotid artery surgery, and aortic aneurysm repair outcomes in the United States. J Vasc Surg. 2024. PMID: 39486599.
    PubMed-indexed articleMeta-analysis / systematic review2024
    PubMedDOI
  43. 43.
    BASIL trial participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925-1934.
    PubMed-indexed article2005

    In patients presenting with severe limb ischaemia due to infra-inguinal disease and who are suitable for surgery and angioplasty, a bypass-surgery-first and a balloon-angioplastic-first strategy are associated with broadly similar outcomes in terms of amputation-free survival, and in the short-term, surgery is more expensive than angiopLasty.

    PubMed
  44. 44.
    Farber A, Menard MT, Conte MS, et al.; BEST-CLI Trial Investigators. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia. N Engl J Med. 2022;387(25):2305-2316.
    PubMed-indexed article2022

    Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban.

    PubMed
  45. 45.
    Bisdas T, et al. Hybrid revascularization strategies. *J Vasc Surg*. 2013;57:116–23. PubMed. Hybrid therapy.
    PubMed-indexed article2013

    complex and simple hybrid procedures enable multilevel revascularizations in high-risk patients with comparable patency and limb salvage and Limb salvage in patients who presented with critical limb ischemia was better in the cHYBRID group than other groups.

    PubMedOpen PDF
  46. 46.
    Jung HJ, Lee SC, Kim KY, Lee SS. Simultaneous Hybrid Operation Common Femoral Endarterectomy and Endovascular Treatment in Multilevel Peripheral Arterial Disease with Critical Limb Ischemia. Indian J Surg. 2018;80(2):140-145.
    PubMed-indexed article2018

    The simultaneous hybrid operation for multilevel revascularization may be feasible to treat inMultilevel PAD with high technical success and limb salvage rates, thus providing an attractive alternative to larger open surgery or endovascular procedures.

    PubMedOpen PDF
  47. 47.
    Almasri J, et al. Surveillance of bypass grafts. *BMJ*. 2018;360:k941. PubMed. Surveillance evidence.
    PubMed-indexed article2018

    Patency rates are highest for saphenous vein bypass, whereas both patency and limb salvage are markedly inferior for prosthetic grafting to below the knee targets, particularly for severe anatomic patterns of disease treated via endovascular means.

    PubMedDOIOpen PDF
  48. 48.
    Mani K, et al. The role of registries in vascular surgery (Swedvasc, Vascunet). *Eur J Vasc Endovasc Surg*. 2020. PubMed
    PubMed-indexed article2020

    Comparison of the UV and green laser data suggests that the green wavelength energy was absorbed less efficiently than the UV wavelength because of differences in absorption at 355 and 532 nm for LiFePO₄.

    PubMedOpen PDF
  49. 49.
    Potier L, et al. Toe pressure and toe–brachial index for PAD in diabetes. *Diabetes Care*. 2011;34:134–9. PubMed. TBI utility.
    PubMed-indexed article2011

    The ABI could be used in patients with diabetes, but values should be interpreted with precision, according to the clinical situation, when there is concomitant clinical peripheral neuropathy or high risk of arterial calcification.

    PubMedDOIOpen PDF
  50. 50.
    Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed. 2022. Ch. 61, Open Surgical Technique, p. 987
    Textbook
    Textbook referenceTextbook2022

    Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed.. 2022. Ch. 61, Open Surgical Technique, p. 987

    Textbook reference
  51. 51.
    Swedvasc Annual Report 2022. National vascular registry, Sweden. Link. Registry outcomes.
    No stable evidence link
    ucr.uu.se2022
    Source
  52. 52.
    Vascunet Collaboration. International vascular surgery outcomes. *Eur J Vasc Endovasc Surg*. 2019;58:345–54. PubMed. Registry data.
    PubMed-indexed article2019

    The physiological effects of xylene, one of representative organic solvents, on the budding yeast Saccharomyces cerevisiae were examined and it was found that xylene induced fragmentation of mitochondria and the nuclear accumulation of Yap1, an oxidative stress responsive transcription factor, followed by the transcriptional activation of its target genes, GPX2 and TRX2, in yeast cells treated with xylene.

    PubMed
  53. 53.
    Writing Committee Members. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. J Am Coll Cardiol. 2024. PMID: 38752899. DOI: 10.1016/j.jacc.2024.02.013.
    PubMed-indexed articleClinical practice guideline2024
    PubMedDOI
  54. 54.
    Uyagu OD, et al. Quality assessment and comparative analysis on the recommendations of current guidelines on screening and diagnosis of peripheral arterial disease: a systematic review. BMJ Open. 2022. PMID: 36104133.
    PubMed-indexed articleMeta-analysis / systematic review2022
    PubMedDOI
  55. 55.
    Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018;7(24):e011245.
    PubMed-indexed article2018

    There is increased risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal artery of the lower limbs.

    PubMedOpen PDF
  56. 56.
    Secemsky EA, Shen C, Schermerhorn M, Yeh RW. Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. JAMA Intern Med. 2021;181(8):1071-1080.
    PubMed-indexed article2021

    DCDs were found to be noninferior to NCDCs in respect to mortality through a median follow-up of 2.72 years and remained robust in analyses and was consistent across prespecified subgroups.

    PubMedOpen PDF

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions